Estimated costs of hospitalization due to coronary artery disease attributable to familial hypercholesterolemia in the Brazilian public health system

• Published in: Archives of Endocrinology and Metabolism Vol. 62; no. 3; pp. 303 - 308
• Main Authors: Bahia, Luciana R, Rosa, Roger S, Santos, Raul D, Araujo, Denizar V
• Format: Journal Article
• Language: English
• Published: Brazil Sociedade Brasileira de Endocrinologia e Metabologia 01-06-2018; Brazilian Society of Endocrinology and Metabolism
• Subjects: Adult; Aged; Brazil; coronary artery disease; Coronary Artery Disease - economics; Coronary Artery Disease - etiology; Coronary Artery Disease - therapy; Costs and cost analysis; Cross-Sectional Studies; familial hypercholesterolemia; Female; Health Care Costs - statistics & numerical data; hospitalization; Hospitalization - economics; Hospitalization - statistics & numerical data; Humans; Hypercholesterolemia - complications; Hypercholesterolemia - economics; Hypercholesterolemia - therapy; Male; Middle Aged; Original; Public Health - economics; Public Health - statistics & numerical data; Retrospective Studies; Risk Factors
• ISSN: 2359-3997; 2359-4292; 2359-4292
• DOI: 10.20945/2359-3997000000030

Cardiovascular diseases are the leading cause of death in Brazil, imposing substantial economic burden on the health care system. Familial hypercholesterolemia (FH) is known to greatly increase the risk of premature coronary artery disease (CAD). This study aimed to estimate the economic impact of hospitalizations due to CAD attributable to FH in the Brazilian Unified Health Care System (SUS).
Retrospective, cross-sectional study of data obtained from the Hospital Information System of the SUS (SIHSUS). We selected all adults (≥ 20 years of age) hospitalized from 2012--2014 with primary diagnoses related to CAD (ICD-10 I20 to I25). Attributable risk methodology estimated the contribution of FH in the outcomes of interest, using international data for prevalence (0.4% and 0.73%) and relative risk for events (RR = 8.56).
Assuming an international prevalence of FH of 0.4% and 0.73%, of the 245,981 CAD admissions/year in Brazil, approximately 7,249 and 12,915, respectively, would be attributable to an underlying diagnosis --of FH. The total cost due to CAD per year, considering both sexes and all adults, was R$ 985,919,064, of which R$ 29,053,500 and R$ 51,764,175, respectively, were estimated to be attributable to FH. The average cost per FH-related CAD event was R$ 4,008.
Based on estimated costs of hospitalization for CAD, we estimated that 2.9-5.3% are directed to FH patients. FH can require early specific therapies to lower risk in families. It is mandatory to determine the prevalence of FH and institute appropriate treatment to minimize the clinical and economic impact of this disease in Brazil.